An interventional study of Automated insulin delivery system - Medtronic 780G in Pregnancy and Type 2 Diabetes, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 27 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 328th largest by planned enrollment of the 333 interventional ones that give a count, is one of 23 that started in 2026, is one of 15 with no phase, reaches primary completion later than 33 of the 37 other live ones, and was the 335th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →27 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Bialystok · Sites in Poland
Ages 18–65
Ascletis Pharma (China) Co., Limited · Sites in Poland, United States, Czechia and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in Poland, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Poland, United States, Argentina and 13 more countries
Ages 18+
Silesian Centre for Heart Diseases · Sites in Poland
Ages 35–75
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 67 · Phase 3 220 · Phase 4 28
First in 2001; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 500 across the 333 interventional studies, 3,039 across the 18 observational. Of the 307 that completed or were terminated, 203 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
335 of 351 have an industry lead sponsor. The 10 most frequent:
Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.
Poznan University of Medical Sciences has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
11 of the studies in Diabetes Mellitus, Type 2 with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT06704672Hoffmann-La RocheClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus | 2027-01-15 |
Add all 11 to your calendar (.ics) → With an account.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-arm interventional study evaluates the MiniMed 780G insulin pump and continuous glucose monitoring (CGM) system in pregnant women with type 2 diabetes enrolled at ≤ 16 weeks gestation. From recruitment to delivery, participants attend regular clinical visits for active insulin adjustments. The primary objective is to measure the percentage of time spent in the target pregnancy glucose range (63-140 mg/dL). Secondary outcomes track mean glucose, HbA1c, and overall maternal and neonatal health to ensure safety and efficacy.
This study will evaluate the use of the MiniMed 780G insulin pump system in pregnant women with type 2 diabetes. The aim is to assess whether this treatment can help participants achieve good glucose control during pregnancy and support favorable maternal and neonatal outcomes.
This is a single-arm interventional study. All participants will use the same insulin pump and continuous glucose monitoring system from recruitment until delivery. The study will include pregnant women with type 2 diabetes who enter the study at 16 weeks of pregnancy or less.
Participants will attend regular follow-up visits during pregnancy. Researchers will review glucose data, adjust insulin treatment, measure HbA1c, and assess pregnancy and neonatal outcomes.
The main outcome is the percentage of time spent in the pregnancy target glucose range of 63 to 140 mg/dL from recruitment until delivery. The study will also assess mean glucose levels, maternal outcomes, and neonatal outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant patients with type 2 diabetes treated with automated insulin delivery system
Device: Automated insulin delivery system - Medtronic 780G
Use of automated insulin delivery system in pregnant patients with type 2 diabetes
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: From enrollment to the delivery
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: From enrollment to the delivery
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 18
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 22
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 26
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 30
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 34
Time in range
Percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: Week 37
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 18
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 22
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 26
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 30
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 34
Time in tight range
Percentage of time spent in target glucose values - 63-120 mg/dL (3.5-6.7 mmol/L)
Time frame: Week 37
Change in the time in range values
Change in percentage of time spent in target glucose values - 63-140 mg/dL (3.5-7.8 mmol/L)
Time frame: From the recruitment to delivery
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 18
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 22
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 26
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 30
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 34
Time above range
Percentage of time spent above target glucose values - \>140 mg/dL (\>7.8 mmol/L)
Time frame: Week 37
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 18
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 22
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 26
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 30
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 34
Time above tight range
Percentage of time spent above target glucose values - \>120 mg/dL (\>6.7 mmol/L)
Time frame: Week 37
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 18
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 22
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 26
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 30
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 34
Time below range
Percentage of time spent below target glucose values - \<63 mg/dL (\<3.5 mmol/L)
Time frame: Week 37
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 18
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 22
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 26
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 30
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 34
Mean sensor glycemia
Average value of glucose concentration measured by the sensor (mg/dL and mmol/L)
Time frame: Week 37
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 18
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 22
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 26
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 30
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 34
Coefficient of variation (%CV)
Metric of glycemic variability measured by the sensor (%)
Time frame: Week 37
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 18
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 22
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 26
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 30
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 34
Standard deviation (SD)
Metric of glycemic variability measured by the sensor (mg/dL and mmol/L)
Time frame: Week 37
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 18
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 22
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 26
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 30
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 34
HbA1C
Blood glycated hemoglobin measurement (% and mmol/mol)
Time frame: Week 37
Severe hypoglycemia episodes
Number of episodes of self-reported severe hypoglycemia.
Time frame: From recruitment until delivery.
Gestational weight gain
Maternal gestational weight gain (kg)
Time frame: From recruitment until delivery
Gestational weight gain from pre-pregnancy
Self-reported maternal gestational weight gain (kg)
Time frame: From pre-pregnancy until delivery
Pregnancy hypertensive disorders
Preeclampsia, Eclampsia, Gestational hypertension
Time frame: From recruitment until delivery
The mode of delivery
Vaginal, c-section, spontaneous, induction of labor
Time frame: At delivery
Birth trauma
IADPSG criteria
Time frame: At delivery
Gestational birth weight
Neonatal birth weight in grams
Time frame: At delivery
Macrosomia
Gestational birth weight \>4200g
Time frame: At delivery
Large-for-gestational-age (LGA)
Neonatal birth weight \>90th percentile
Time frame: At delivery
Small-for-gestational-age (SGA)
Neonatal birth weight \<10th percentile
Time frame: At delivery
Placental weight
Measured in grams
Time frame: At delivery
Gestational age
Timing of delivery
Time frame: At delivery
Preterm birth
\<37 weeks
Time frame: At delivery
Number of neonates with respiratory distress syndrome
Defined as the number of neonates diagnosed with respiratory distress syndrome during the postnatal hospital stay, based on clinical signs of respiratory distress and the need for respiratory support, with or without radiological confirmation, according to local neonatal clinical practice.
Time frame: From delivery until hospital discharge, assessed up to 20 weeks postpartum
Number of neonates with jaundice requiring phototherapy
Defined as the number of neonates diagnosed with neonatal jaundice requiring phototherapy during the postnatal hospital stay. Phototherapy requirement will be determined according to local neonatal clinical practice based on serum or transcutaneous bilirubin assessment.
Time frame: From delivery until hospital discharge, assessed up to 20 weeks postpartum
Number of neonates with neonatal hypoglycemia
Neonatal hypoglycemia - glucose concentrations in neonatal blood \<40 mg/dL (2.2 mmol/L) in a single laboratory measurement at least 3 hours after birth, in the first 24 hours of life
Time frame: Assessed from delivery until 24 hours postpartum
Stillbirth
Pregnancy loss after 22 weeks
Time frame: From week 22
Neonatal length of hospital stay
Duration of neonatal hospitalization, measured in days
Time frame: From date of delivery until the date of hospital discharge, assessed up to 20 weeks
Length of stay in the neonatal intensive care unit (NICU)
Duration of NICU stay, measured in days
Time frame: From date of NICU admission until the date of NICU discharge, assessed up to 20 weeks
Neonatal acidosis
Umbilical pH \<7.15
Time frame: At delivery
Apgar score
Apgar score \<8
Time frame: At delivery
Plan to share: No
Started May 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 29 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poznan University of Medical Sciences →